Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Leases (2019 - 2025)

ImmunityBio (IBRX) has disclosed Leases for 7 consecutive years, with $33.0 million as the latest value for Q4 2025.

  • Quarterly Leases fell 1.06% to $33.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.0 million through Dec 2025, down 1.06% year-over-year, with the annual reading at $33.0 million for FY2025, 1.06% down from the prior year.
  • Leases for Q4 2025 was $33.0 million at ImmunityBio, down from $33.2 million in the prior quarter.
  • The five-year high for Leases was $48.1 million in Q2 2022, with the low at $18.4 million in Q1 2021.
  • Average Leases over 5 years is $36.1 million, with a median of $35.1 million recorded in 2024.
  • The sharpest move saw Leases surged 171.26% in 2021, then decreased 22.87% in 2023.
  • Over 5 years, Leases stood at $36.3 million in 2021, then grew by 26.12% to $45.8 million in 2022, then dropped by 20.19% to $36.5 million in 2023, then fell by 8.7% to $33.4 million in 2024, then dropped by 1.06% to $33.0 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $33.0 million, $33.2 million, and $34.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.